Endocrinology · Gastrinoma

Genetics, MEN1, and Family Implications

At a Glance

About 20% to 30% of people with gastrinoma have MEN1, an inherited condition that can affect the parathyroid, pancreas or duodenum, and pituitary. Genetic counseling and testing can guide lifelong monitoring and help first-degree relatives learn whether they need surveillance.

One of the most important steps in your journey is determining if your gastrinoma is “sporadic” (occurring by chance) or part of a genetic condition called Multiple Endocrine Neoplasia Type 1 (MEN1). Roughly 20% to 30% of people with gastrinomas have MEN1 ^[1]^[2].

The answer to this question changes everything—from how your surgeon approaches the tumor to how your family members are monitored for the rest of their lives.

What is MEN1?

MEN1 is an autosomal-dominant hereditary condition caused by a change (mutation) in the MEN1 gene, which normally acts as a “tumor suppressor” to keep cells from growing out of control ^[3]. When this gene doesn’t work correctly, tumors can form in several different hormone-producing glands. The three most common areas affected are known as the “3 Ps” ^[3]^[4]:

Parathyroid: Almost 95-100% of people with MEN1 will develop overactive parathyroid glands (primary hyperparathyroidism) by age 50 ^[5]^[6]. This leads to high calcium levels in the blood, which can cause kidney stones and bone thinning.
Pancreas and Duodenum: This includes gastrinomas, as well as other neuroendocrine tumors (NETs) ^[2].
Pituitary: Tumors in the pituitary gland (at the base of the brain) can affect growth, metabolism, and reproductive hormones ^[5]^[7].

Why the Distinction Matters

If you have a sporadic gastrinoma, it is usually a single, isolated tumor. Surgeons often aim for a cure by removing that one tumor and the nearby lymph nodes ^[8]^[9].

However, MEN1-associated gastrinomas are different. They are often multifocal, meaning there are many tiny, microscopic tumors scattered throughout the duodenum ^[2]^[10]. Because of this, the decision to have surgery is much more complex and often debated by experts ^[10]^[11]. Management depends on the tumor’s growth rate, grade, symptoms, acid control, and location, as well as the expertise of the center. In many MEN1 cases, doctors may choose to manage the acid with medication and monitor the tumors closely, reserving surgical options like pancreaticoduodenectomy for particular anatomic or oncologic situations rather than mandating it solely due to MEN1 status ^[10]^[9].

Screening and “Cascade” Testing

Because MEN1 is autosomal dominant, there is a 50% chance that a parent with the gene will pass it on to each of their children ^[3].

For You: Your doctor will likely start with biochemical screening by checking your blood for high calcium and a hormone called PTH (parathyroid hormone). They may also check prolactin levels to look for pituitary issues ^[1]^[7]. If MEN1 is suspected, you will be offered formal germline testing through genetic counseling. Lack of a family history does not exclude MEN1.
For Your Family: If you test positive for a known pathogenic MEN1 mutation, your first-degree relatives (parents, siblings, and children) should be offered cascade testing ^[12]^[13]. Finding the specific familial variant early allows them to start surveillance. A true negative result for that specific known variant means they can generally avoid a lifetime of scans ^[12]^[14], but an uninformative negative test does not exclude the condition.

Lifelong Surveillance

If you are diagnosed with MEN1, you will need a specialized care team for life. This usually includes a “high-volume” center where surgeons, endocrinologists, and radiologists see hundreds of these cases ^[15]. Surveillance is guideline-based and highly individualized ^[16]^[15]:

Annual Blood Work: To monitor calcium, gastrin, and other hormone levels.
Periodic Imaging: Rather than a blanket schedule, abdominal imaging intervals and modalities vary, and pituitary MRI is generally guided by biochemical findings or symptoms, limiting cumulative ionizing-radiation exposure ^[17]^[15].

While an MEN1 diagnosis adds a layer of complexity, it also provides a roadmap for your future health. With modern monitoring, most people with MEN1 can lead long, active lives ^[18].

Common questions in this guide

Could my duodenal gastrinoma be part of MEN1?

Yes. A gastrinoma can occur by itself or as part of MEN1, an inherited condition caused by a change in the MEN1 gene. About 20% to 30% of people with gastrinomas have MEN1, which can also affect the parathyroid, pancreas or duodenum, and pituitary.

What tests check whether I have MEN1?

Doctors commonly start with blood tests for calcium and parathyroid hormone, also called PTH, and may check prolactin for pituitary problems. If MEN1 is suspected, a genetic counselor can arrange testing of the MEN1 gene. A lack of family history does not rule out MEN1.

What does a positive MEN1 result mean for my family?

MEN1 is passed in an autosomal-dominant pattern, so a parent with the mutation has a 50% chance of passing it to each child. Parents, siblings, and children of someone with a confirmed MEN1 mutation should be offered testing for that specific family variant. A true negative for the known variant generally means the relative does not need MEN1 surveillance, but an uninformative negative result does not rule it out.

Does MEN1 mean I need surgery for my gastrinoma?

Not necessarily. MEN1-associated gastrinomas are often multiple small tumors, so doctors weigh tumor growth, grade, size, symptoms, acid control, location, and lymph node or cancer-related findings. Medication and close monitoring may be appropriate, while operations such as pancreaticoduodenectomy are reserved for selected situations rather than required solely because MEN1 is present.

What monitoring is needed if I have MEN1?

Lifelong follow-up usually includes annual blood tests for calcium, gastrin, and other hormones. Imaging is individualized, and pituitary MRI is generally guided by blood-test results or symptoms to limit unnecessary radiation. Care is often coordinated through a high-volume multidisciplinary team with endocrine specialists, surgeons, and radiologists.

Get notified when new evidence is published on duodenal gastrin-producing neuroendocrine tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
Assessing for Multiple Endocrine Neoplasia Type 1 in Patients Evaluated for Zollinger-Ellison Syndrome-Clues to a Safer Diagnostic Process.
Singh Ospina N, Donegan D, Rodriguez-Gutierrez R, et al.
The American journal of medicine 2017; (130(5)):603-605 doi:10.1016/j.amjmed.2016.11.035.
PMID: 28011308
2
Contemporary surgical management of the Zollinger-Ellison syndrome in multiple endocrine neoplasia type 1.
Albers MB, Manoharan J, Bartsch DK
Best practice & research. Clinical endocrinology & metabolism 2019; (33(5)):101318 doi:10.1016/j.beem.2019.101318.
PMID: 31521501
3
Multiple Endocrine Neoplasia Type 1: A Case Report With Review of Imaging Findings.
Keller HR, Record JL, Lall NU
Ochsner journal 2018; (18(2)):170-175 doi:10.31486/toj.17.0019.
PMID: 30258300
4
[Multiple endocrine neoplasia type 1: about a case].
Anguezomo G, El Mghari G, El Ansari N
The Pan African medical journal 2019; (33()):238 doi:10.11604/pamj.2019.33.238.18053.
PMID: 31692695
5
Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database.
Giusti F, Cianferotti L, Boaretto F, et al.
Endocrine 2017; (58(2)):349-359 doi:10.1007/s12020-017-1234-4.
PMID: 28132167
6
Intraoperative Decision-Making and Technical Aspects of Parathyroidectomy in Young Patients With MEN1 Related Hyperparathyroidism.
Nobecourt PF, Zagzag J, Asare EA, Perrier ND
Frontiers in endocrinology 2018; (9()):618 doi:10.3389/fendo.2018.00618.
PMID: 30459713
7
Update on the clinical management of multiple endocrine neoplasia type 1.
Pieterman CRC, Valk GD
Clinical endocrinology 2022; (97(4)):409-423 doi:10.1111/cen.14727.
PMID: 35319130
8
Recurrence after surgical resection of nonmetastatic sporadic gastrinoma: Which prognostic factors and surgical procedure?
Robin L, Sauvanet A, Walter T, et al.
Surgery 2023; (173(5)):1144-1152 doi:10.1016/j.surg.2022.12.030.
PMID: 36781315
9
Surgical management of Zollinger-Ellison syndrome: Classical considerations and current controversies.
Shao QQ, Zhao BB, Dong LB, et al.
World journal of gastroenterology 2019; (25(32)):4673-4681 doi:10.3748/wjg.v25.i32.4673.
PMID: 31528093
10
How to treat gastrinomas in patients with multiple endocrine neoplasia type1: surgery or long-term proton pump inhibitors?
Imamura M, Komoto I, Taki Y
Surgery today 2023; (53(12)):1325-1334 doi:10.1007/s00595-022-02627-z.
PMID: 36473964
11
Pancreaticoduodenectomy Is the Best Surgical Procedure for Zollinger-Ellison Syndrome Associated with Multiple Endocrine Neoplasia Type 1.
Kong W, Albers MB, Manoharan J, et al.
Cancers 2022; (14(8)) doi:10.3390/cancers14081928.
PMID: 35454834
12
Impact of Delay in Diagnosis in Outcomes in MEN1: Results From the Dutch MEN1 Study Group.
van Leeuwaarde RS, van Nesselrooij BP, Hermus AR, et al.
The Journal of clinical endocrinology and metabolism 2016; (101(3)):1159-65 doi:10.1210/jc.2015-3766.
PMID: 26751192
13
Genetics of multiple endocrine neoplasia type 1 syndrome: what's new and what's old.
Falchetti A
F1000Research 2017; (6()) doi:10.12688/f1000research.7230.1.
PMID: 28184288
14
The future: genetics advances in MEN1 therapeutic approaches and management strategies.
Agarwal SK
Endocrine-related cancer 2017; (24(10)):T119-T134 doi:10.1530/ERC-17-0199.
PMID: 28899949
15
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice.
Brandi ML, Pieterman CRC, English KA, et al.
The lancet. Diabetes & endocrinology 2025; (13(8)):699-721 doi:10.1016/S2213-8587(25)00119-6.
PMID: 40523372
16
American Association of Clinical Endocrinology Consensus Statement on Management of Multiple Endocrine Neoplasia Type 1.
Del Rivero J, Gangi A, Annes JP, et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025; doi:10.1016/j.eprac.2025.02.001.
PMID: 40232217
17
Screening and surveillance practices for Multiple Endocrine Neoplasia type 1-related Neuroendocrine Tumours in European Neuroendocrine Tumor Society Centers of Excellence (ENETS CoE)-An ENETS MEN1 task force questionnaire study.
Pieterman CRC, Grozinsky-Glasberg S, O'Toole D, et al.
Journal of neuroendocrinology 2025; (37(1)):e13468 doi:10.1111/jne.13468.
PMID: 39587981
18
Sporadic and MEN1-related gastrinoma and Zollinger-Ellison syndrome: differences in clinical characteristics and survival outcomes.
Massironi S, Rossi RE, Laffusa A, et al.
Journal of endocrinological investigation 2023; (46(5)):957-965 doi:10.1007/s40618-022-01961-w.
PMID: 36436191

This page explains MEN1 genetics, testing, and family screening in people with duodenal gastrinoma for educational purposes; it is not medical advice. Discuss your test results, treatment choices, and surveillance plan with your genetic counselor and neuroendocrine tumor care team.